Shenzhen Chipscreen Biosciences Co (688321) fair value: what the stock is really worth
As of Oct 21, 2026: fair value (intrinsic value) of Shenzhen Chipscreen Biosciences Co stock ¥2.49, price ¥22.59, upside -89.0%, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 22, 2026.
How to read this chart
60‑month range ¥13.01 – ¥46.19 · fair‑value band ¥2.49 – ¥2.86 · the ¥22.59 price screens above the ¥2.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 22, 2026.
Follow Shenzhen Chipscreen Biosciences Co in your weekly email
Every Wednesday you see whether Shenzhen Chipscreen Biosciences Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs.
Show moreShow less
The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor.
It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192 a highly selective JAK3 kinase inhibitor.
The company was founded in 2001 and is headquartered in Shenzhen, China.
Stock analysis
Shenzhen Chipscreen Biosciences Co (688321) currently trades at ¥22.59, while our model-based Fair Value estimate is ¥2.49, 89.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥4.11 per share, and 0 of the 13 models we run sit above the ¥22.59 price.
Bear case: the Dividend Discount group reads lowest at ¥0.9300, and 13 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥2.49 (bear) to ¥2.86 (bull), the price of ¥22.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shenzhen Chipscreen Biosciences Co reported revenue of 910M CNY in FY2025 versus 430M CNY in FY2021, a compound +20.6%/yr. Reported net income was 51.1M CNY in FY2025, compounding +23.5%/yr from FY2021.
Key figures
Market cap 10.0B CNY (≈ $1.5B) Small · P/E ratio 102.7 · P/S ratio 9.56 · EPS (TTM) ¥0.2200 · Dividend yield 0.3% · Net margin 8.9% · Return on equity 4.5% · Return on assets (EBIT) 0.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −23% fair-value upside, at −89%, 688321 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0400 to ¥10.14). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥2.49Fair Value ¥2.49Bull¥2.86
Price ¥22.59 · Upside -89.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1309 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+38.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+18.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.5%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.5% vs 22.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 6%
Compare Shenzhen Chipscreen Biosciences Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 576 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−89.0% · Bottom 25%
Profitability
Return on equity (12 months)4.5% · Below median
Return on assets1.4% · Below median
Net margin (12 months)8.9% · Above median
Operating margin (12 months)20.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)17.1% · Above median
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity0.63× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)102.7× · Priciest 25%
P/B6.04× · Priciest 25%
P/S (12 months)9.56× · Priciest 25%
EV/EBITDA51.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)86· sector 25
PAST (return on equity)18· sector 28
HEALTH (low debt)69· sector 96
DIVIDEND (yield)5· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shenzhen Chipscreen Biosciences Co Fair Value". https://www.fairvalue-calculator.com/stock/688321
Frequently asked questions
Is Shenzhen Chipscreen Biosciences Co (688321) overvalued or undervalued?
As of Oct 22, 2026, our model estimates a fair value of ¥2.49 versus a price of ¥22.59, about −89% upside (overvalued).
What is the fair value of 688321?
Our model-based fair value for Shenzhen Chipscreen Biosciences Co is ¥2.49 (as of Oct 22, 2026), built from audited fundamentals. The current price: ¥22.59.
What is the quality score of 688321?
Shenzhen Chipscreen Biosciences Co has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shenzhen Chipscreen Biosciences Co (688321)?
Our model-based price target is the fair value of ¥2.49 (as of Oct 22, 2026) from 14 valuation models. Cautious scenario ¥2.49, optimistic scenario ¥2.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Shenzhen Chipscreen Biosciences Co stock forecast for 2026?
Our models put fair value at ¥2.49, about −89% upside versus a price of ¥22.59 (overvalued). Cautious scenario ¥2.49, optimistic scenario ¥2.86. The calculation is refreshed regularly with new filings.
What is the revenue of Shenzhen Chipscreen Biosciences Co (688321)?
Shenzhen Chipscreen Biosciences Co reported trailing-twelve-month revenue of about 1.0B CNY (latest available figure, as of Oct 22, 2026).
Does Shenzhen Chipscreen Biosciences Co pay a dividend?
Shenzhen Chipscreen Biosciences Co currently shows a dividend yield of 0.26% relative to its recent price (as of Oct 22, 2026).
What is the intrinsic value of Shenzhen Chipscreen Biosciences Co (688321)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shenzhen Chipscreen Biosciences Co it is ¥2.49 per share (as of Oct 22, 2026), against a price of ¥22.59. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Shenzhen Chipscreen Biosciences Co stock overvalued or undervalued in 2026?
As of Oct 22, 2026, 688321 trades above its calculated fair value: price ¥22.59, fair value ¥2.49, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688321?
No. The price is what the market pays today (¥22.59); the fair value is what the company's own numbers justify (¥2.49). For Shenzhen Chipscreen Biosciences Co the two are ¥20.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shenzhen Chipscreen Biosciences Co worth?
The market values Shenzhen Chipscreen Biosciences Co at about 10.0B CNY (market capitalisation, as of Oct 22, 2026). Per share that is ¥22.59; our models calculate a fair value of ¥2.49 per share.
What do the bullish and bearish scenarios say about 688321?
Our models span a range for Shenzhen Chipscreen Biosciences Co: cautious scenario ¥2.49, base ¥2.49, optimistic ¥2.86 per share (as of Oct 22, 2026, price ¥22.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688321?
Shenzhen Chipscreen Biosciences Co trades at a price-to-earnings ratio of 102.7 (as of Oct 22, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥2.49 is built from several models across several years. Other multiples: P/B 6.0, P/S 9.6, EV/EBITDA 51.4.
How solid is the balance sheet of Shenzhen Chipscreen Biosciences Co (688321)?
Balance-sheet figures for Shenzhen Chipscreen Biosciences Co (as of Oct 22, 2026): return on equity 4.5%, debt of 0.63 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 688321 from its 52-week high?
Shenzhen Chipscreen Biosciences Co trades at ¥22.59, about 36% below its 52-week high of ¥35.25 and 4% above the low of ¥21.79 (as of Oct 21, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.49 is for.
Which stocks are comparable to Shenzhen Chipscreen Biosciences Co?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shenzhen Chipscreen Biosciences Co stock attractive at the current price?
The data as of Oct 22, 2026: price ¥22.59, calculated fair value ¥2.49 (−89%), Quality Score 54/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688321 calculated?
We run Shenzhen Chipscreen Biosciences Co through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.49, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6 % above its aggregate fair value. Shenzhen Chipscreen Biosciences Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shenzhen Chipscreen Biosciences Co (688321)?
The closing price on Oct 21, 2026 was ¥22.59. Our model-based fair value is ¥2.49, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shenzhen Chipscreen Biosciences Co right now?
The price sits above even our optimistic bull case (¥2.86). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥2.49 to ¥2.86), unusually little disagreement for a valuation.
Key figures of Shenzhen Chipscreen Biosciences Co
How large is the market capitalisation of Shenzhen Chipscreen Biosciences Co (688321)?
The market capitalisation of Shenzhen Chipscreen Biosciences Co is 10.0B CNY (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shenzhen Chipscreen Biosciences Co (688321)?
The price-to-sales ratio of Shenzhen Chipscreen Biosciences Co is 9.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shenzhen Chipscreen Biosciences Co (688321)?
Earnings per share at Shenzhen Chipscreen Biosciences Co are ¥0.2200 (price ÷ EPS = P/E 102.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shenzhen Chipscreen Biosciences Co (688321)?
The dividend yield of Shenzhen Chipscreen Biosciences Co is 0.3% (payout 26.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shenzhen Chipscreen Biosciences Co (688321)?
The net margin of Shenzhen Chipscreen Biosciences Co is 8.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shenzhen Chipscreen Biosciences Co (688321)?
The return on equity (ROE) of Shenzhen Chipscreen Biosciences Co is 4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shenzhen Chipscreen Biosciences Co (688321)?
On an EBIT basis the return on assets of Shenzhen Chipscreen Biosciences Co is 0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shenzhen Chipscreen Biosciences Co (688321)?
The operating margin of Shenzhen Chipscreen Biosciences Co is 20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shenzhen Chipscreen Biosciences Co (688321)?
Revenue at Shenzhen Chipscreen Biosciences Co is growing +17.1% versus a year earlier (3y avg +19.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shenzhen Chipscreen Biosciences Co (688321)?
Earnings per share at Shenzhen Chipscreen Biosciences Co are growing −18.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shenzhen Chipscreen Biosciences Co (688321) generate?
The free cash flow of Shenzhen Chipscreen Biosciences Co is −81.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shenzhen Chipscreen Biosciences Co (688321) carry?
The net debt of Shenzhen Chipscreen Biosciences Co is 848M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shenzhen Chipscreen Biosciences Co in the live analysis
One click puts Shenzhen Chipscreen Biosciences Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 22, 2026